Envelope determinants for dual-receptor specificity in feline leukemia virus subgroup A and T variants

Heather H Cheng1, Maria M Anderson, F Claire Hankenson

  • 1Division of Human Biology, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N., Mail Stop C3-168, Seattle, WA 98109-1024, USA.

Journal of Virology
|January 28, 2006
PubMed

Insights

Mutations in the feline leukemia virus (FeLV) envelope glycoprotein determine receptor specificity. Specific N- and C-terminal changes enable entry via the nonclassical FeLV-T receptor pathway, distinct from the classical FeLV-A pathway.

Area of Science:

  • Virology
  • Molecular Biology
  • Structural Biology

Background:

  • Gammaretroviruses, like feline leukemia virus (FeLV), utilize transport proteins as receptors for cell entry.
  • Some FeLV subgroups, such as FeLV-T, require a nonclassical receptor complex involving a transport protein (Pit1) and a soluble cofactor (FeLIX).

Purpose of the Study:

  • To identify the specific regions of the FeLV envelope glycoprotein that dictate receptor specificity for classical versus nonclassical pathways.
  • To understand how mutations influence the interaction of FeLV with its cellular receptors.

Main Methods:

  • Engineering mutations into the FeLV-A envelope glycoprotein backbone, including N-terminal and C-terminal alterations.
  • Assessing the receptor specificity of engineered viruses by measuring infection and binding to cells expressing FeLV-A or FeLV-T receptors.

Main Results:

  • FeLV-A receptor specificity was retained with N-terminal mutations (positions 6, 7, or 8), though infection efficiency varied.
  • Combined N-terminal mutations with C-terminal modifications (4-amino-acid insertion and adjacent change) conferred FeLV-T receptor specificity.
  • A W-->L change at position 378 enhanced infectivity in some cases.

Conclusions:

  • Determinants in both the N- and C-termini of the FeLV envelope surface unit can direct viral entry through the nonclassical FeLV-T receptor pathway.
  • The established receptor binding domain of gammaretroviral envelope proteins independently mediates FeLV-A receptor entry, irrespective of FeLV-T determinants.